Modern Medicine Cases

Doctors gain from the advantages of both active and passive investingThe debate between active investment strategies, meaning hands-on investing with a portfolio manager’s help to beat the market, and passive investment, holding onto securities through the market’s ups and downs, is unlikely to subside any time soon.
HPI: Context and modifying factorsThe different elements of the history of present illness.
2017 EHR Report Card
2017 EHR Report CardElectronic health records (EHRs) now are a part of most medical practices, yet doctors remain unhappy with them. In the Medical Economics 2017 EHR report—our fifth—we let them explain why in their own words.
Poor design hampers EHR usability, doctors sayFinding an EHR designed solely for improving patient care remains a source of simmering frustration, judging by the results of the Medical Economics 2017 EHR Report.
Inability to share information across systems remains major EHR failureFinding an EHR designed solely for improving patient care remains a source of simmering frustration, judging by the results of the Medical Economics 2017 EHR Report.
Doctors to EHR vendors: You need our inputFinding an EHR designed solely for improving patient care remains a source of simmering frustration, judging by the results of the Medical Economics 2017 EHR Report.
Top 11 gripes physicians have with patients
Top 11 gripes physicians have with patientsWe asked primary care physicians from around the country what their top gripes with patients have been, and their answers may surprise you—or relate to you wholeheartedly. Read on to find out what they had to say.
Intravitreal brimonidine holds promise for slowing GA growthBrimonidine Drug Delivery System (Brimo DDS) in an intravitreally administered, sustained-release implant (Allergan) shows promise as a treatment for geographic atrophy (GA), secondary to age-related macular degeneration in a phase IIa clinical trial.
Novel brolucizumab fosters as real-world alternative for nAMDTopline results from phase III studies investigating intravitreal brolucizumab (Novartis) for treatment of neovascular age-related macular degeneration (nAMD) support the potential of this novel anti-VEGF antibody to meet the real-world need for an alternative agent with a sustainable therapeutic regimen.
Why are EHRs still so terrible?
Why are EHRs still so terrible?Unfortunately, the federal government has pulled the pin and tossed it into the exam room, resulting in an explosion of inefficiency and a disruption in patient care and communication.